echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Takeda released three-year data on dengue vaccination: the effective rate reached 62%, and the hospitalization protection rate was 84%

    Takeda released three-year data on dengue vaccination: the effective rate reached 62%, and the hospitalization protection rate was 84%

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On May 24, Takeda Pharmaceutical announced the results of a 3-year follow-up of its dengue vaccine TAK-003 in the global phase 3 clinical study (TIDES).

    The data shows that although the vaccine efficacy diminishes with time, the effective rate of TAK-003 to prevent dengue infection can still reach 62.
    0%.

    Dengue fever, commonly known as "breakbone fever", is the fastest-spreading mosquito-borne viral disease that can infect people of all ages.
    It is listed by the World Health Organization (WHO) as one of the top ten global health threats in 2019.

    It is estimated that globally, dengue fever will cause 390 million infections and about 20,000 deaths every year, and it is the leading cause of serious diseases among children in some countries in Latin America and Asia.

    TAK-003 is an attenuated quadrivalent dengue vaccine, developed based on the attenuated dengue serotype 2 virus (DENV-2), which provides a genetic backbone for all four vaccine viruses.

    In Phase 1 and Phase 2 clinical trials, vaccinated teenagers developed immune responses to all four dengue viruses, and they were safe and well tolerated.

    TIDES is a four-and-a-half-year, randomized, double-blind, placebo-controlled pivotal trial to verify the preventive effect of TAK-003 in children aged 4 to 16 who have been exposed to and have not been exposed to dengue fever.

    The study included more than 20,000 healthy children and adolescents in dengue-endemic areas in Latin America and Asia.

    Previous data showed that the overall effectiveness of the vaccine in protecting participants from dengue fever in the 12th and 18th months after the completion of the two doses of vaccination was 80.
    2% and 73.
    3%, respectively.This time Takeda released the data 36 months after the participants received two doses of the vaccine.
    The overall effectiveness of TAK-003 was 62.
    0% (95% CI: 56.
    6% to 66.
    7%), and the effective rate of preventing hospitalization was 83.
    6% (95%).
    % CI: 76.
    8% to 88.
    4%).

    At the same time, TAK-003 was generally well tolerated, and no major safety risks were observed.

    Derek Wallace, Vice President and Global Dengue Fever Program Director of Takeda, said: "Our dengue vaccine candidate can last for three years to protect against dengue fever and is particularly effective in preventing hospitalization.
    The
    above results make me more confident that TAK-003 can help solve the global problem.
    A huge burden of dengue fever. "End Reference: [1] Takeda Pharmaceutical official website [2] Giving-it-a-leg selected onlookers in the past Nature publication: Accelerate the production of heat by fat tissue, it is difficult to think about not being thin! Hot article Cell publication: The cause of intestinal inflammation and infection has been found, and they are all caused by pizza and burgers Curse! The Lancet is a heavyweight! Early cancer screening cannot reduce the mortality of ovarian cancer.
    What will happen to patients with advanced cancer? The latest research of the Cell sub-Journal found that Allure Red and Sunset Yellow, which are widely used in food, can induce and accelerate the colon Inflammation development! Rewen will increase the effect of immunotherapy by nearly three times! Will this anti-cancer vaccine that enters Phase 1 clinical cancer "terminator"? Medical immunotherapy | biosimilars | vaccines | drug resistance | drug targets Point| Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Basic Research on Drug Side Effects/ Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestine Dao Microbial Medical Devices/Biotechnology In Vitro Diagnostics | Medical Devices | Bio-Nano| 3D Printing | Genetic Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anticancer Drugs | 4+7 Quantity Procurement | Consumables | Filing system | Registrant system | Healthy China | New edition of the basic drug catalog | AI medical devices | Telemedicine | Same-share non-rights market/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext | R & D Investment | Acquisition | Market & Consumption
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.